RxDoctor Payments Data

Martin Backman, MD

Neurology · Santa Ana, CANPI 1699738385

Payments from drug & device makers

$89,526in general payments, 2019–2025

Across 700 payments — averaging $127.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$69K
  • Novartis$11K
  • Teva Pharmaceuticals USA, Inc.$1K
  • AbbVie$994
  • Neurocrine Biosciences, Inc.$762
  • UCB, Inc.$760
  • plus $5K from 42 others

What the payments were for

  • Food & beverage$10,33397%
  • Education$3063%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$89,526 in reported general payments places this provider in the 85th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$75,569
Medicare patients
166
Services billed
386

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CuvitruImmun Glob G(Igg)/Gly/Iga Ov5013$270,664
CopaxoneGlatiramer Acetate29$167,850
Austedo XrDeutetrabenazine11$142,451
Gamunex-CImmune Globul G/Gly/Iga Avg 4611$126,234
TecfideraDimethyl Fumarate11$102,668
NeuproRotigotine41$33,234
QuliptaAtogepant19$22,785
Rivastigmine47$8,630
Levetiracetam237$7,876
Tegretol XrCarbamazepine12$4,930
Lacosamide64$4,513
Memantine Hcl222$4,453
CarbatrolCarbamazepine12$4,088
Carbamazepine ErCarbamazepine28$3,854
Carbidopa-LevodopaCarbidopa/Levodopa139$3,509

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Copaxone, Austedo Xr$1,266$310,30140 claims
Takeda Pharmaceuticals U.S.A., Inc.Cuvitru$74$270,66413 claims
Grifols USA, LLCGamunex-C$45$126,23411 claims
BiogenTecfidera$679$102,66811 claims
UCB, Inc.Neupro$760$33,23441 claims
AbbVieQulipta$994$22,78519 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,996 neurology providers in California.

Other neurology in Santa Ana

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →